German firm Boehringer Ingelheim will close its small molecule research facility in Connecticut, US, laying off 120 people. The company will also eliminate 60 staff in other functions in Connecticut, and reduce its US sales force by an additional 64.

The news comes after Boehringer Ingelheim said in June that it would eliminate about 725 positions in the US. Beginning in 2017, the company will form a new group, led out of Connecticut, to focus on cancer immunology research. It will result in approximately 35 new positions in the state.